Phase II study evaluating the efficacy of Lenalidomide in association with Rituximab in refractory or relapse of primary central nervous system lymphoma (PCNSL)
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2019
Price : $35 *
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary) ; Dexamethasone
- Indications CNS cancer; Diffuse large B cell lymphoma; Lymphoma
- Focus Proof of concept; Therapeutic Use
- Acronyms REVRI
- 09 Jul 2019 Status changed from active, no longer recruiting to completed.
- 04 Feb 2019 Planned End Date changed from 1 Jan 2019 to 1 Apr 2019.
- 29 Jan 2019 Results published in the Annals of Oncology